Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
Special Offer: Just $199
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
THE BEST BLACK FRIDAY DEAL YET (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
THE BEST BLACK FRIDAY DEAL YET (Ad)
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
THE BEST BLACK FRIDAY DEAL YET (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
THE BEST BLACK FRIDAY DEAL YET (Ad)
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
THE BEST BLACK FRIDAY DEAL YET (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
THE BEST BLACK FRIDAY DEAL YET (Ad)
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
THE BEST BLACK FRIDAY DEAL YET (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
THE BEST BLACK FRIDAY DEAL YET (Ad)
NASDAQ:BGNE

BeiGene - BGNE Stock Forecast, Price & News

$174.97
-6.82 (-3.75%)
(As of 11/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$171.93
▼
$179.00
50-Day Range
$125.51
▼
$207.71
52-Week Range
$118.18
▼
$368.50
Volume
136,701 shs
Average Volume
206,119 shs
Market Capitalization
$18.14 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$239.50

BeiGene MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
36.9% Upside
$239.50 Price Target
Short Interest
Bearish
2.07% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.58mentions of BeiGene in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$10.27 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($17.69) to ($12.51) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

680th out of 1,044 stocks

Pharmaceutical Preparations Industry

319th out of 510 stocks

See Top Rated MarketRank™ Stocks Here
BGNE stock logo

About BeiGene (NASDAQ:BGNE) Stock

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

BGNE Stock News Headlines

November 25, 2022 | markets.businessinsider.com
SVB Securities Keeps Their Buy Rating on BeiGene (BGNE)
November 24, 2022 | americanbankingnews.com
BeiGene (NASDAQ:BGNE) Trading Down 5.6%
November 22, 2022 | finance.yahoo.com
BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022
November 22, 2022 | americanbankingnews.com
Brokers Set Expectations for BeiGene, Ltd.'s FY2022 Earnings (NASDAQ:BGNE)
November 20, 2022 | americanbankingnews.com
BeiGene (NASDAQ:BGNE) Upgraded by StockNews.com to "Hold"
November 20, 2022 | americanbankingnews.com
BeiGene, Ltd. (NASDAQ:BGNE) CEO Sells $5,171,000.00 in Stock
November 20, 2022 | americanbankingnews.com
BeiGene, Ltd. (NASDAQ:BGNE) to Post FY2024 Earnings of ($10.93) Per Share, Jefferies Financial Group Forecasts
November 17, 2022 | finance.yahoo.com
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)
November 17, 2022 | americanbankingnews.com
BeiGene (NASDAQ:BGNE) PT Raised to $210.00 at Guggenheim
November 10, 2022 | finance.yahoo.com
BeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare Blood Cancers
November 4, 2022 | finance.yahoo.com
BeiGene to Present at Upcoming Investor Conferences
November 3, 2022 | finance.yahoo.com
BeiGene to Present Dynamic View of Development Programs for Hematologic Malignancies at 64th ASH Meeting
November 3, 2022 | finance.yahoo.com
Is This Chinese Pharmaceutical Stock Worth the Risk?
November 2, 2022 | finance.yahoo.com
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
October 19, 2022 | finance.yahoo.com
AnHeart Therapeutics Expands US Team with Appointments in Clinical Research and Medical Affairs - Yahoo Finance
October 18, 2022 | benzinga.com
New Drugs Approvals Bring No Relief for Ailing Innovent Bio - BeiGene (NASDAQ:BGNE), Eli Lilly (NYSE:LLY) - Benzinga
October 18, 2022 | finance.yahoo.com
ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site - Yahoo Finance
October 17, 2022 | finance.yahoo.com
Investors ignore increasing losses at BeiGene (NASDAQ:BGNE) as stock jumps 16% this past week - Yahoo Finance
October 17, 2022 | finance.yahoo.com
Investors ignore increasing losses at BeiGene (NASDAQ:BGNE) as stock jumps 16% this past week
October 15, 2022 | marketwatch.com
BeiGene Gets Positive CHMP Opinion for Brukinsa for Chronic Lymphocytic Leukemia - MarketWatch
October 14, 2022 | benzinga.com
BeiGene shares are trading higher after the company announced the CHMP of the European Medicines Agency issued a positive opinion recommending approval of BRUKINSA for the treatment of adult patients with chronic lymphocytic leukemia. - BeiGene ( - Benzinga
October 14, 2022 | finance.yahoo.com
European Heath Agency's Committee Backs Approving BeiGene's Brukinsa In Leukemia Setting
October 14, 2022 | marketwatch.com
BeiGene Says Brukinsa Drug Bested Rival at Trial - MarketWatch
October 14, 2022 | businesswire.com
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLL - Business Wire
October 14, 2022 | seekingalpha.com
BeiGene Brukinsa shows better survival vs Imbruvica in blood cancer patients in trial - Seeking Alpha
See More Headlines
Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

BGNE Company Calendar

Last Earnings
11/04/2021
Today
11/27/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/24/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BGNE
CUSIP
N/A
CIK
1651308
Web
www.beigene.com
Phone
861085148500
Fax
N/A
Employees
8,200
Year Founded
2010

Price Target and Rating

Average Stock Price Forecast
$239.50
High Stock Price Forecast
$296.00
Low Stock Price Forecast
$210.00
Forecasted Upside/Downside
+36.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($21.35)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-1,413,350,000.00
Net Margins
-171.94%
Pretax Margin
-169.38%
Return on Equity
-38.92%
Return on Assets
-27.93%

Debt

Debt-to-Equity Ratio
0.04
Current Ratio
4.07
Quick Ratio
3.87

Sales & Book Value

Annual Sales
$1.18 billion
Price / Sales
15.43
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$44.89 per share
Price / Book
3.90

Miscellaneous

Outstanding Shares
103,700,000
Free Float
95,923,000
Market Cap
$18.14 billion
Optionable
Optionable
Beta
0.82

Social Links


Key Executives

  • Mr. John V. OylerMr. John V. Oyler (Age 54)
    Co-Founder, Exec. Chairman & CEO
    Comp: $1.75M
  • Dr. Xiaobin Wu Ph.D. (Age 60)
    Pres, COO & GM of China
    Comp: $1.64M
  • Dr. Xiaodong Wang Ph.D. (Age 59)
    Co-Founder, Chairman of Scientific Advisory Board & Non-Exec. Director
    Comp: $250k
  • Ms. Julia Wang (Age 51)
    CFO & Principal Accounting Officer
    Comp: $798.14k
  • Mr. Wang Lai (Age 45)
    Global Head of R&D
    Comp: $1.13M
  • Dr. Edna Huang M.D. (Age 49)
    Consultant
    Comp: $768.08k
  • Mr. Daniel Maller
    VP of Fin. & Accounting
  • Ms. Mi Zhou
    Sr. Director of Investor Relations
  • Mr. Kevin C. Mannix
    Sr. VP of Investor Relations.
  • Ms. Diana Lee Francis
    VP and Global Head of Quality & Regulatory Compliance

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BGNE Stock - Frequently Asked Questions

Should I buy or sell BeiGene stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BGNE shares.
View BGNE analyst ratings or view top-rated stocks.

What is BeiGene's stock price forecast for 2023?

5 Wall Street analysts have issued 12 month price targets for BeiGene's shares. Their BGNE share price forecasts range from $210.00 to $296.00. On average, they anticipate the company's stock price to reach $239.50 in the next year. This suggests a possible upside of 36.9% from the stock's current price.
View analysts price targets for BGNE or view top-rated stocks among Wall Street analysts.

How have BGNE shares performed in 2022?

BeiGene's stock was trading at $270.93 at the beginning of 2022. Since then, BGNE shares have decreased by 35.4% and is now trading at $174.97.
View the best growth stocks for 2022 here.

When is BeiGene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 24th 2023.
View our BGNE earnings forecast.

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($4.46) earnings per share for the quarter, topping the consensus estimate of ($4.70) by $0.24. The firm had revenue of $206.44 million for the quarter, compared to analyst estimates of $185.70 million. BeiGene had a negative trailing twelve-month return on equity of 38.92% and a negative net margin of 171.94%.

What is John V. Oyler's approval rating as BeiGene's CEO?

58 employees have rated BeiGene Chief Executive Officer John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among the company's employees. 42.0% of employees surveyed would recommend working at BeiGene to a friend.

What other stocks do shareholders of BeiGene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Block (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).

When did BeiGene IPO?

(BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

What is BeiGene's stock symbol?

BeiGene trades on the NASDAQ under the ticker symbol "BGNE."

Who are BeiGene's major shareholders?

BeiGene's stock is owned by a number of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (4.57%), Baillie Gifford & Co. (3.10%), Temasek Holdings Private Ltd (3.00%), BlackRock Inc. (2.69%), State Street Corp (0.72%) and Price T Rowe Associates Inc. MD (0.43%). Insiders that own company stock include Amgen Inc, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Ltd Beigene, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends.

How do I buy shares of BeiGene?

Shares of BGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BeiGene's stock price today?

One share of BGNE stock can currently be purchased for approximately $174.97.

How much money does BeiGene make?

BeiGene (NASDAQ:BGNE) has a market capitalization of $18.14 billion and generates $1.18 billion in revenue each year. The company earns $-1,413,350,000.00 in net income (profit) each year or ($21.35) on an earnings per share basis.

How many employees does BeiGene have?

The company employs 8,200 workers across the globe.

How can I contact BeiGene?

BeiGene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The official website for the company is www.beigene.com. The company can be reached via phone at 861085148500 or via email at ir@beigene.com.

This page (NASDAQ:BGNE) was last updated on 11/27/2022 by MarketBeat.com Staff